XTX202, an IL-2 mutein linked to an inactivation domain that could be cleaved by tumor proteases in the TME, induced potent tumor growth inhibition without systemic toxicity or peripheral immune activation in mouse models,547 and it is currently undergoing clinical evaluation (Table 3). Here, IL2 is linked to neoplasm.